ANI Pharmaceuticals launched 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder. The current annual U.S. market for these two strengths of the product is approximately $505M. ANI also launched Erythromycin Ethylsuccinate for Oral Suspension 400mg/5mL, indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $16M
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.